Clinical Trial Update: A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing amivantamab plus FOLFIRI to cetuximab/bevacizumab plus FOLFIRI in patients with KRAS/NRAS and BRAF wild-type colorectal cancer; recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Adrucil (5-fluorouracil)
• Avastin (bevacizumab)
• Camptosar (irinotecan)
• ERBITUX (cetuximab)
• Leucovorin (folinic acid)
• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colorectal Neoplasms | Phase 3 | Status: RECRUITING